European Commission Appoints CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, to the European Innovation Council Advisory Board
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, congratulates CureVac co-founder and Chairman of the Supervisory Board, Ingmar Hoerr, following his appointment as a Member of the European Innovation Council (EIC) Advisory Board.
On June 27, the European Commission introduced the EIC, which will focus on transforming scientific discoveries into new businesses and accelerate the scale-up of innovative companies.
“Ingmar’s appointment to this important Commission is testament to his foundational scientific research and company building expertise which steered CureVac from the lab to industry leader,” said Dan Menichella, Chief Executive Officer of CureVac. “We benefit from Ingmar’s strategic guidance on the development of mRNA therapeutics and know that his passion, vision and leadership will ably guide the EIC’s development and mission execution.”
The EIC is currently in its pilot phase and will formally launch in 2021 under the next EU research and innovation program, Horizon Europe, with a proposed €10 billion budget.
https://www.curevac.com/en/newsroom/news/european-commission-appoints-curevac-co-founder-supervisory-board-chairman-ingmar-hoerr-to-the-e/